AstraZeneca Rejigs Respiratory Franchise With Fresh Covis Deal
Licenses Out Eklira and Duaklir For $270m
Having got hold of two COPD drugs from Spain's Almirall in 2014, AstraZeneca has passed Eklira and Duaklir onto old partner Covis Pharma as it focuses on more targeted respiratory therapies.
